Biotechnology
Lexaria's DehydraTECH-Semaglutide Shows Promising Reduction in Side Effects Compared to Rybelsus®
Lexaria Bioscience Corp. reports interim results from its Phase 1b study, showing DehydraTECH-semaglutide significantly reduces gastrointestinal and overall side effects compared to Rybelsus®, potentially improving patient adherence to treatment.
ABVC BioPharma Receives $100,000 Milestone Payment from OncoX BioPharma, Strengthening Oncology Partnership
ABVC BioPharma's latest milestone payment from OncoX BioPharma underscores the growing commercial value of their oncology platform and the potential for global market expansion in botanical-based cancer treatments.
GeoVax Shifts Gedeptin® Strategy to Neoadjuvant Combination Trial After KEYNOTE-689 Success
GeoVax Labs, Inc. announces a strategic pivot in its Gedeptin® clinical development program towards a neoadjuvant therapy combination with pembrolizumab for head and neck squamous cell carcinoma, following promising KEYNOTE-689 Phase 3 trial results.
Creative Biolabs Unveils Next-Generation CAR-T Engineering Platform for Smarter, Safer Cancer Therapy
Creative Biolabs introduces its Next CAR-T Engineering Platform, aiming to enhance the safety and efficacy of CAR-T cell therapy through advanced modular genetic programming and robust construct design.
Akari Therapeutics CEO Unveils Novel ADC Platform Targeting Cancer Resistance
Akari Therapeutics, under CEO Abizer Gaslightwala, is pioneering a novel ADC platform aimed at overcoming cancer resistance and enhancing treatment durability through immune system activation.
GeoVax to Announce Q2 2025 Financial Results and Corporate Update
GeoVax Labs, Inc. is set to disclose its second quarter 2025 financial outcomes and a corporate update, highlighting its progress in vaccine and immunotherapy development for infectious diseases and cancer.
Creative Biolabs Advances Precision Immunotherapy with Fc Engineering Technology
Creative Biolabs' innovative Fc engineering technology enhances the therapeutic performance of biologics by optimizing immune effector functions, offering new avenues for treating cancers and autoimmune diseases.
Creative Biolabs Enhances Cell Therapy Research with Advanced iPSC and Macrophage Solutions
Creative Biolabs introduces innovative tools and services for iPSC neural differentiation and macrophage isolation, significantly advancing cell therapy research and disease modeling.
Lantern Pharma Reports First Complete Response in Phase 1 LP-284 Trial for Aggressive DLBCL
Lantern Pharma's LP-284 shows promising results in a Phase 1 trial for aggressive DLBCL, marking a significant step forward in the treatment of refractory lymphomas.
Calidi Biotherapeutics Inc. to Showcase RedTail Platform and Oncology Advancements in Investor Webinar
Calidi Biotherapeutics Inc. (NYSE American: CLDI) will host an investor webinar to discuss its RedTail platform and advancements in oncology, highlighting the potential of its CLD-401 candidate to eliminate tumors and activate immune memory.
Aditxt Inc. to Showcase Adimune's Innovations in Autoimmune Therapeutics During July 22 Livestream
Aditxt Inc. (NASDAQ: ADTX) will host a livestream to discuss Adimune Inc.'s advancements in autoimmune therapeutics, highlighting the subsidiary's innovative approach and the growing market opportunities.
Lantern Pharma Secures EU Patent for AI-Designed Cancer Drug LP-284
Lantern Pharma's EU patent for LP-284, an AI-designed cancer drug, marks a significant step in global commercialization and treatment for non-Hodgkin’s lymphoma.
Creative Biolabs Advances Precision Medicine with Dual 3D Organoid and Tissue Slice Models
Creative Biolabs is enhancing precision medicine research by integrating 3D organoid and precision-cut tissue slice models, offering a more accurate and efficient approach to drug testing and disease modeling.
Lantern Pharma Engages IBN for Corporate Communications Strategy Amid AI-Driven Oncology Pipeline Advancements
Lantern Pharma partners with IBN to enhance investor awareness as it progresses its AI-driven oncology pipeline, including therapies for lung, brain, breast, and blood cancers.
BioRestorative Therapies Reports Promising Phase 2 Trial Results for Chronic Pain Treatment
BioRestorative Therapies' phase 2 trial results for BRTX-100 show significant improvement in function and pain reduction for chronic lumbar disc disease patients, potentially paving the way for accelerated FDA approval.
Kairos Pharma Ltd. to Showcase Oncology Innovations at H.C. Wainwright Global Investment Conference
Kairos Pharma Ltd. (NYSE American: KAPA) will present its advancements in cancer therapeutics at the H.C. Wainwright 27th Annual Global Investment Conference, highlighting its potential to address drug resistance in cancer treatments.
GeoVax Advances Mpox Vaccine Development Amid Global Outbreak Concerns
GeoVax Labs accelerates its GEO-MVA vaccine candidate development following EMA's streamlined approval pathway, addressing the urgent need for diversified Mpox vaccine supply as global outbreaks expand.
Community Foundation of Broward Awards $900,000 in Grants for Cancer Research
The Community Foundation of Broward has awarded two grants totaling $900,000 to support innovative cancer research and treatment accessibility in Broward County, focusing on lung cancer biomarkers and melanoma immunotherapies.
Soligenix Inc. Anticipates Key Catalysts in 2025 for Rare Disease Treatments
Soligenix Inc. is poised for significant advancements in its rare disease treatment pipeline, with key updates expected in 2025 that could impact its stock valuation and the medical community.
Diopter Technologies Advances Ocular Disease Treatment with Dissolving Contact Lens
Diopter Technologies has completed early clinical studies for a dissolving amniotic membrane biopolymer contact lens, offering a novel approach to treating ocular surface diseases by delivering growth factors directly to the eye.
GeoVax to Showcase Vaccine and Cancer Therapy Progress at Emerging Growth Conference
GeoVax Labs, Inc. will present updates on its GEO-MVA, GEO-CM04S1, and Gedeptin® programs at the Emerging Growth Conference, highlighting advancements in vaccine development and cancer therapy.
NanoViricides Advances MPox Treatment with Adaptive Clinical Trial Design
NanoViricides, Inc. nears finalization of an adaptive clinical trial protocol for NV-387, a potential first-in-class treatment for MPox, highlighting its significance amid limited effective therapies.
Sino Biological Introduces ProPure™ Endotoxin-Free Proteins, Enhancing Research and Therapeutic Development
Sino Biological US, Inc. launches ProPure™, a line of ultra-pure, endotoxin-free recombinant proteins produced in the USA, setting a new industry standard for research and therapeutic applications.
Nutriband Inc. Founder Shares Vision and Strategy on Smart Money Circle Podcast
Nutriband Inc.'s founder Serguei Melnik discusses the company's unique approach to biotech entrepreneurship and its revenue-generating products on the Smart Money Circle Show, highlighting its potential for long-term value.
Calidi Biotherapeutics Featured in NetworkNewsWire Spotlight on Genetic Medicines
Calidi Biotherapeutics' innovative approach to treating hard-to-treat cancers with engineered viruses is highlighted in a NetworkNewsWire editorial, showcasing its potential to transform cancer treatment and address autoimmune disorders.
Creative Biolabs Advances ADC Therapy with Precision Toxin Design and Pharmacokinetic Analysis
Creative Biolabs highlights the intricate balance and design behind ADC therapy, emphasizing the importance of toxin precision and pharmacokinetic studies for effective cancer treatment.
ABVC BioPharma Achieves $150K Milestone in Licensing Strategy, Highlighting Growth in Botanical Therapeutics
ABVC BioPharma's recent $150,000 milestone payment from AiBtl BioPharma underscores the success of its licensing-first strategy and the growing interest in its CNS-focused botanical therapeutics.
Intelligent Bio Solutions Inc. to Showcase Fingerprint Sweat PK Study at ADLM 2025 Clinical Lab Expo
Intelligent Bio Solutions Inc. will present its pharmacokinetic study data at the ADLM 2025 Clinical Lab Expo, highlighting the reliability of fingerprint sweat as a non-invasive diagnostic tool for drug screening.
Calidi Biotherapeutics Inc. Secures $4.6 Million Through Warrant Exercise Agreement
Calidi Biotherapeutics Inc. has raised $4.6 million by exercising outstanding warrants, funding its innovative cancer treatment research and development efforts.
Jupiter Neurosciences Advances in Treating Neuroinflammation and Aging with JOTROL™ and Nugevia™
Jupiter Neurosciences Inc. is making strides in treating central nervous system disorders and tapping into the longevity market with its innovative products JOTROL™ and Nugevia™, highlighting the potential to combat aging and neuroinflammation.